Stroke care company Imperative Care Inc revealed on Friday the appointment of Daniel Davis as its chief operating officer.
In the senior position in the company, Davis is responsible for the launch and growth of the breakthrough technologies to treat ischemic stroke patients in the US.
Most recently, Davis has served as chief commercial officer and president of North America, Penumbra, where he launched the first FDA-cleared aspiration system for neurovascular mechanical thrombectomy.
The company said Davis brings 19 years of experience in sales, marketing, and business development with both early stage and Fortune 500 medical device, technology and consumer product companies, focused on bringing neurovascular innovations to market.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval